Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • TG6050
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: 2020

    Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

    20201221 – CTA Approval BT-001 – EN

    Published 21 December 2020
    Categorized as 2020, BT-001, BT-001 (EN), Invir.IO, Press release

    Transgene Announces Financial Calendar for 2021

    20191217 Financial calendar 2021 EN

    Published 17 December 2020
    Categorized as 2020, Press release

    Transgene Announces Investor Meetings for January 2021

    20201216 PR Investors Meeting agenda Jan 2021

    Published 16 December 2020
    Categorized as 2020, Press release

    Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020

    20201203 – TG4001 mini oral prez ESMO IO EN

    Published 3 December 2020
    Categorized as 2020, Press release, TG4001, TG4001

    Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer

    20201203 – Nomination Transgene – EN

    Published 3 December 2020
    Categorized as 2020, Press release

    Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

    Franck Gallardo, et al. Biomedicines, November 26 2020 – Read the article Publication

    Published 26 November 2020
    Categorized as 2020, Invir.IO, Publication

    Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

    20201109 Transgene BioInvent_SITC BT001_EN

    Published 9 November 2020
    Categorized as 2020, BT-001, BT-001 (EN), Invir.IO, Press release

    Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020

    20201109 – TG4001+avelumab presentation poster SITC – EN

    Published 9 November 2020
    Categorized as 2020, Press release, TG4001, TG4001

    BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

    Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation

    Published 9 November 2020
    Categorized as 2020, BT-001, BT-001 (EN), Invir.IO, Publication, publication HP en

    TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity

    Poster SITC TG4001 C. Le Tourneau et al. SITC 2020 Download the poster here Poster Presentation

    Published 9 November 2020
    Categorized as 2020, Publication, publication HP en, TG4001

    Posts navigation

    Page 1 … Page 5 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo